{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T03:13:34Z","timestamp":1648523614224},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.eimc.2011.12.007","type":"journal-article","created":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T05:04:18Z","timestamp":1329973458000},"page":"542-548","source":"Crossref","is-referenced-by-count":0,"title":["La pr\u00e1ctica de un tratamiento antirretroviral emp\u00edrico es dependiente del porcentaje de resistencias primarias del virus de la inmunodeficiencia humana"],"prefix":"10.1016","volume":"30","author":[{"given":"Clotilde","family":"Fern\u00e1ndez Guti\u00e9rrez Del \u00c1lamo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"L\u00f3pez Tinoco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Soto C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Lozano Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Bernal Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Guerrero S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Gir\u00f3n-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2011.12.007_bib0005","first-page":"e1","article-title":"Documento de consenso de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2011)","volume":"29","author":"Panel de expertos de Gesida y Plan Nacional del Sida","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2011.12.007_bib0010","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [consultado 1 Jul 2011]. Department of Health and Human Services. January 10, 2011; 1\u2013166. Disponible en: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"10.1016\/j.eimc.2011.12.007_bib0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2011.12.007_bib0020","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)","volume":"171","author":"Schuurman","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcv.2009.03.002","article-title":"Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure","volume":"45","author":"Balduin","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.eimc.2011.12.007_bib0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/QAI.0b013e3181ba11e8","article-title":"Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy","volume":"52","author":"Geretti","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2011.12.007_bib0035","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/496984","article-title":"Resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis","volume":"41","author":"Sax","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0040","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1086\/496988","article-title":"Resistance testing in drug-naive HIV-infected patients: is it time","volume":"41","author":"Hecht","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2011.05.010","volume":"91","author":"Garc\u00eda","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eimc.2011.12.007_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00002030-199912240-00001","article-title":"Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy","volume":"13","author":"Devereux","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.12.007_bib0055","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/QAD.0b013e3283034953","article-title":"Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy","volume":"22","author":"Peuchant","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.12.007_bib0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0025-7753(00)71663-0","article-title":"Grupo Espa\u00f1ol Multic\u00e9ntrico para el Estudio de Seroconvertores. El per\u00edodo de incubaci\u00f3n del sida en Espa\u00f1a antes de la terapia antirretroviral de alta eficacia","volume":"115","author":"Moreno","year":"2000","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimc.2011.12.007_bib0065","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1086\/420745","article-title":"Primary HIV type 1 infection","volume":"38","author":"Kassutto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0070","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.163.17.2097","article-title":"Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings","volume":"163","author":"Weintrob","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2011.12.007_bib0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/595704","article-title":"Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection","volume":"48","author":"Dalmau","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0080","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted human immunodeficiency virus type 1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.eimc.2011.12.007_bib0085","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/427212","article-title":"Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for Soutine resistance screening before initiation of antiretroviral therapy","volume":"40","author":"Novak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0095","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bmj.38665.534595.55","article-title":"Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study","volume":"331","author":"Cane","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.eimc.2011.12.007_bib0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"Simen","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0105","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/496982","article-title":"Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain","volume":"41","author":"De Mendoza","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2011.12.007_bib0110","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1157\/13108707","article-title":"Resistencias primarias a los f\u00e1rmacos antirretrovirales en los pacientes diagnosticados de infecci\u00f3n por el VIH en Gran Canaria entre los a\u00f1os 2002-2005","volume":"25","author":"S\u00e1nchez","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2011.12.007_bib0115","doi-asserted-by":"crossref","first-page":"e5575","DOI":"10.1371\/journal.pone.0005575","article-title":"Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial","volume":"4","author":"Zolopa","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2011.12.007_bib0120","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/QAD.0b013e3283463c07","article-title":"Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection","volume":"25","author":"Gay","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.12.007_bib0125","unstructured":"European AIDS Clinical Society EACS Guidelines [consultado 1 Jul 2011]. October 2011. Disponible en: http:\/\/www. europeanaidsclinicalsociety.org"},{"key":"10.1016\/j.eimc.2011.12.007_bib0130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/QAD.0b013e3282f5e062","article-title":"Transmission of drug-resistant HIV-1 in Europe remains limited to single classes","volume":"22","author":"SPREAD Programme","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2011.12.007_bib0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN Joint project): a European multicohort study","volume":"11","author":"Wittkop","year":"2011","journal-title":"Lancet Infect Dis"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X12000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X12000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T14:38:02Z","timestamp":1640875082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X12000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0213005X12000341"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2011.12.007","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}